Drug Substance Manufacturing - Mammalian Cell Cultures

Proven track record in ‘downstream- processing- only’ services Service description: - Intermediate materials, that need to be further purified and/or conjugated - Hormones or other recombinant proteins like virus like particles from inclusion bodies or from biomass - Peptides from inclusion bodies, biom...

High throughput process development services for E. coli and yeast based on high degree of automation and digitalization to speed up time to clinic for diverse protein formats e.g., scaffolds, enzymes, pDNA, sub-unit vaccines and antibody fragments. Service description: - Genetic engineering, cell line an...

Efficient tech transfers from customers or within own global bio-manufacturing network, launch preparation and commercial supply readiness for drug substance and drug product. Service description: - Long-standing track record in product launches - 47 biopharmaceuticals brought to the market - Tailored to...

12,000 L  commercial manufacturing capacity in multi-licensed facility  Two trains  each with 6,000 L of capacity which can be used with flexible scales
Large-scale GMP facilities licensed by EMA, FDA & MHLW for clinical and commercial global supplies 
Protein refol...

• Clinical and commercial capacities and technology for vials  • Formulations for liquids and lyophilizates vials (flexible vial sizes from 2 mL to 100 mL) • Flexible filling volumes for clinical and commercial supply  • Manual and automated visual inspections  • Globally licensed ...

The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA).